miltefosine

Known as: hexadecyl 2-(trimethylazaniumyl)ethyl phosphate, n-hexadecylphosphorylcholine, Choline Phosphate Hexadecyl Ester, Hydroxide, Inner Salt 
An orally- and topically-active alkyl-phosphocholine compound with potential antineoplastic activity. Miltefosine targets cellular membranes… (More)
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2007
Review
2007
Visceral leishmaniasis (VL) is a systemic protozoan disease that is transmitted by phlebotomine sandflies. Poor and neglected… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
Highly Cited
2006
Highly Cited
2006
The antitumor drug miltefosine has been recently approved as the first oral drug active against visceral leishmaniasis. We have… (More)
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
Review
2005
Review
2005
Governed by parasite and host factors and immunoinflammatory responses, the clinical spectrum of leishmaniasis encompasses… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
Highly Cited
2004
Highly Cited
2004
The oral agent miltefosine has demonstrated a >95% cure rate in Indian visceral leishmaniasis. We performed a large, placebo… (More)
  • table 1
  • table 2
  • table 3
  • table 4
  • table 5
Is this relevant?
Highly Cited
2004
Highly Cited
2004
Miltefosine (hexadecylphosphocholine [HePC]) has proved to be a potent oral treatment for human visceral leishmaniasis due to… (More)
  • figure 1
  • figure 3
  • figure 2
  • figure 5
  • figure 4
Is this relevant?
Highly Cited
2004
Highly Cited
2004
Miltefosine causes leishmanial death, but the possible mechanism(s) of action is not known. The mode of action of miltefosine was… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
Highly Cited
2002
Highly Cited
2002
BACKGROUND There are 500,000 cases per year of visceral leishmaniasis, which occurs primarily in the Indian subcontinent. Almost… (More)
Is this relevant?
Highly Cited
2001
Highly Cited
2001
There is no recognized oral treatment for American cutaneous leishmaniasis. A rising-dose, open-label phase I/II trial of the… (More)
Is this relevant?
Highly Cited
1999
Highly Cited
1999
BACKGROUND There is no effective orally administered medication for any leishmania infection. We investigated miltefosine, which… (More)
Is this relevant?
Highly Cited
1998
Highly Cited
1998
BACKGROUND There is no effective oral treatment for visceral leishmaniasis (kala-azar), a disseminated intracellular protozoal… (More)
Is this relevant?